Stanol ester margarine alone and with simvastatin lowers serum cholesterol in families with familial hypercholesterolemia caused by the FH- North Karelia mutation

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 2, 2000, Pages 500-506

  Vuorio, Alpo F ^a   Gylling, Helena ^a   Turtola, Hannu ^b   Kontula, Kimmo ^a   Ketonen, Pirjo ^b   Miettinen, Tatu A ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NORTH KARELIA CENTRAL HOSPITAL   (Finland)

Author keywords

Atherosclerosis; Cholesterol; Familial hypercholesterolemia; Prevention; Stanol ester margarine

Indexed keywords

ALPHA CAROTENE; ALPHA TOCOPHEROL; BETA CAROTENE; CAMPESTEROL; CHOLESTANOL; CHOLESTEROL; DESMOSTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LATHOSTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MARGARINE; RAPESEED OIL; RETINOL; SIMVASTATIN; SITOSTANOL; SITOSTEROL; TRIACYLGLYCEROL; VITAMIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DIET THERAPY; FAMILIAL HYPERCHOLESTEROLEMIA; FAT INTAKE; FEMALE; GENE MUTATION; HETEROZYGOSITY; HUMAN; ISCHEMIC HEART DISEASE; LIPID ABSORPTION; MALE; PRIORITY JOURNAL;

EID: 0033973734     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.2.500     Document Type: Article

References (48)

1. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle DS, eds. The Metabolic and Molecular Bases of Inherited Diseases. 7th ed. New York, NY: McGraw-Hill Book Co; 1995:1981-2030.
2. Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat. 1992;1: 445-466.
3. Vuorio AF, Turtola H, Piilahti K-M, Repo P, Kanninen T, Kontula K. Familial hypercholesterolemia in the Finnish North Karelia: a molecular, clinical and genealogical study. Arterioscler Thromb Vasc Biol. 1997;17: 3127-3138.
4. Koivisto U-M, Turtola H, Aalto-Setälä K, Top B, Frants RR, Kontula K. The familial hypercholesterolemia (FH)-North Karelia mutation of the low density lipoprotein receptor deletes seven nucleotides of exon 6 and is a common cause of FH in Finland. J Clin Invest. 1992;90:219-228.
5. Ferriéres J, Lambert J, Lussier-Cacan S, Davignon J. Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation. Circulation. 1995;92:290-295.
6. WHO MONICA Project. Myocardial infarction and coronary deaths in the World Health Organization WHO MONICA Project: registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in 4 continents. Circulation. 1994;90:583-612.
7. Pimstone SN, Sun X-M, du Souich C, Frohlich JJ, Hayden MR, Soutar AK. Phenotypic variation in heterozygous familial hypercholesterolemia: a comparison of Chinese patients with the same or similar mutations in the LDL receptor gene in China or Canada. Arteriorscler Thromb Vasc Biol. 1998;18:309-315.
8. Miettinen TA, Puska P, Gylling H, Vanhanen H, Vartiainen E. Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med. 1995;333:1308-1312.
9. Koivisto U-M, Hämäläinen L, Taskinen M-R, Kettunen K, Kontula K. Prevalence of familial hypercholesterolemia among young North Karelian patients with coronary heart disease: a study based on diagnosis by polymerase chain reaction. J Lipid Res. 1993;34:269-277.
10. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high cholesterol in adults (Adult Treatment Panel II). Circulation. 1994;89:1329-1345.
11. Friedewald WT, Levy RI, Fredrickson DS. Estimation of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
12. Miettinen TA, Tilvis RS, Kesäniemi A. Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am J Epidemiol. 1990;131: 20-31.
13. Miettinen TA, Koivisto P. Non-cholesterol sterols and bile acid production in hypercholesterolaemic patients with ileal bypass. In: Paumgartner G, Stiehl A, Gerok W, eds. Bile Acids and Cholesterol in Health and Disease. Boston, Mass: MTP Press; 1983:183-187.
14. Miettinen TA. Cholesterol metabolism during ketoconazole treatment in man. J Lipid Res. 1988;29:43-51.
15. Schäfer Elinder L, Walldius G. Simultaneous measurement of serum probucol and lipid-soluble antioxidants. J Lipid Res. 1992;33:131-137.
16. Havekes LM, de Knijff P, Beisiegel U, Havinga J, Smit M, Klausen E. A rapid micromethod for apolipoprotein E phenotyping directly in serum. J Lipid Res. 1987;28:455-463.
17. Study Group, European Atherosclerosis Society. The recognition and management of hyperlipidaemia in adults: a policy statement of the European Atherosclerosis Society. Ear Heart J. 1990;9:571-600.
18. Kwiterovich PO Jr, Levy RI, Fredrickson DS. Neonatal diagnosis of familial type-II hyperlipoproteinemia. Lancet. 1973;1:118-122.
19. Vuorio AF, Turtola H, Kontula K. Neonatal diagnosis of familial hypercholesterolemia in newborns born to a parent with a molecularly defined heterozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1997;17:3332-3337.
20. Buja LM, Kovanen PT, Bilheimer DW. Cellular pathology of homozygous familial hypercholesterolemia. Am J Pathol. 1979;97: 327-358.
21. Gylling H, Siimes MA, Miettinen TA. Sitostanol ester margarine in dietary treatment of children with familial hypercholesterolemia. J Lipid Res. 1995;36:1807-1812.
22. Gylling H, Miettinen TA. Effects of inhibiting cholesterol absorption and synthesis on cholesterol and lipoprotein metabolism in hypercholesterolemic non-insulin-dependent diabetic men. J Lipid Res. 1996;37: 1776-1785.
23. Gylling H, Radhakrishnan R, Miettinen TA. Reduction of serum cholesterol in postmenopausal women with previous myocardial infarction and cholesterol malabsorption induced by dietary sitostanol ester margarine: women and dietary sitostanol. Circulation. 1997;96:4226-4231.
24. Stein E, Kreisberg R, Miller V, Mantell G, Washington L, Shapiro DR, Multicenter Group, I: effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Arch Intern Med. 1990; 150:341-345.
25. Betteridge DJ, Bhatnager D, Bing RF, Durrington PN, Evans GR, Flax H, Jay RH, Lewis-Barned N, Mann J, Matthews DR, Miller JP, Reckless JPD, Sturley R, Taylor KG, Winder AF. Treatment of familial hypercholesterolemia: United Kingdom lipid clinics study of pravastatin and cholestyramine. BMJ. 1992;304:1335-1338.
26. Gylling H, Miettinen TA. Lipid lowering by inhibition of synthesis and absorption of cholesterol during bile acid binding resin. 70th EAS Congress Abstractbook. Geneva, Switzerland: European Atherosclerosis Society; 1998:157.
27. Leren TP, Hjermann. Is responsiveness to lovastatin treatment in familial hypercholesterolemia heterozygotes influenced by the specific mutation in the low-density lipoprotein? Eur J Clin Invest. 1995;25:967-973.
28. Vuorio AF, Ojala J-P, Sarna S, Turtola H, Tikkanen MJ, Kontula K. Heterozygous familial hypercholesterolaemia: the influence of the mutation type of the low-density-lipoprotein receptor gene and PvuII polymorphism of the normal allele on serum lipid levels and response to lovastatin treatment. J Intern Med. 1995;237:43-48.
29. Sun X-M, Patel DD, Knight BL, Soutar AK, The Familial Hypercholesterolaemia Regression Study Group. Influence of genotype at the low density lipoprotein (LDL) receptor gene locus on the clinical phenotype and response to lipid-lowering drug therapy in heterozygous familial hypercholesterolemia. Atherosclerosis. 1998;136:175-185.
30. Naoumova RP, Marais AD, Mountney J, Firth JC, Rendell NB, Taylor GW, Thompson GR. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolemia. Atherosclerosis. 1996;119:201-213.
31. Miettinen TA, Gylling H, Strandberg T, Sarna S, for the Finnish 4S Investigators. Baseline serum cholestanol as a predictor of recurrent coronary events in subgroup of Scandinavian Simvastatin Survival Study. BMJ. 1998;316:1127-1129.
32. Miettinen TA, Strandberg T, Vanhanen HT, Gylling H, for the 4S Group. Noncholesterol serum sterols in Scandinavian Simvastatin Survival Study. In: Gotto AM Jr, Paoletti R, Smith LC, Catapan AL, Jackson AS, eds. Drugs Affecting Lipid Metabolism: Risk Factors and Future Directions. Dordrecht/Boston/London: Kluwer Academic Publishers; 1996:473-476.
33. Lees AM, Mok HYI, Lees RS, McCluskey MA, Grundy SM. Plant sterols as cholesterol-lowering agents: clinical trials in patients with hypercholesterolemia and studies of sterol balance. Atherosclerosis. 1977;28: 325-338.
34. Weststrate JA, Meijer GW. Plant sterol-enriched margarines and reduction of plasma total- and LDL-cholesterol concentrations in normocholesterolemic and mildly hypercholesterolemic subjects. Eur J Clin Nutr. 1998;52:334-343.
35. Bhattacharyya AK, Connor WE. β-Sitosterolemia and xanthomatosis: a newly described lipid storage disease in two sisters. J Clin Invest. 1974; 53:1033-1043.
36. Miettinen TA, Vanhanen H. Dietary sitostanol related to absorption, synthesis and serum level of cholesterol in different apolipoprotein E phenotypes. Atherosclerosis. 1994;105:217-226.
37. Vanhanen HT, Kajander J, Lehtovirta H, Miettinen TA. Serum levels, absorption efficiency, faecal elimination and synthesis of cholesterol during increasing doses of dietary sitostanol esters in hypercholesterolaemic subjects. Clin Sci. 1994;87:61-67.
38. Gylling H, Miettinen TA. Serum cholesterol and lipoprotein metabolism in hypercholesterolaemic NIDDM patients before and during sitostanol ester-margarine treatment. Diabetologia. 1994;37:773-780.
39. Gylling H, Puska P, Vartiainen E, Miettinen TA. Serum retinol, α-tocopherol, carotenes and lipid peroxide production during serum cholesterol lowering by sitostanol ester margarine in a mildly hypercholesterolemic population. Circulation. 1997;94(suppl I):I-578. Abstract.
40. Costantino JP, Kuller LH, Begg L, Redmont CK, Bates MW. Serum level changes after administration of pharmacologic dose of β-carotene. Am J Clin Nutr. 1995;48:1277-1283.
41. Hendersson CT, Mobarhan S, Bowen P, Stacewicz-Sapuntzakis M, Langenberg P, Kiani R, Lucchesi D, Sugerman S. Normal serum response to oral β-carotene in humans. J Am Coll Nutr. 1989;8:625-635.
42. Postaire E, Kouyate D, Rousset G, Regnault C, Lati E, Bejot M, Gossioux P, Hazebroucq G. Plasma concentrations of β-carotene, vitamin A and vitamin E after β-carotene and vitamin E intake. Biomed Chromatogr. 1993;7:136-138.
43. Johnson EJ, Suter PM, Sahyoun N, Ribaya-Mercado JD, Russell RM. Relation between β-carotene intake and plasma and adipose tissue concentrations of carotenoids and retinoids. Am J Clin Nutr. 1995;62: 598-603.
44. Crouse JR, Grundy SM. Effects of sucrose polyester on cholesterol metabolism in man. Metabolism. 1979;28:994-1000.
45. Weststrate JA, Ho van Het KH. Sucrose polyester and plasma carotenoid concentrations in healthy subjects. Am J Clin Nutr. 1995;62:591-597.
46. Kleinman RE, Schneeman B. Olestra and the FDA. N Engl J Med. 1996;335:668.
47. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and β-carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. 1994;330:1029-1035.
48. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL Jr, Valanis B, Williams JH, Barnhart S, Hammar S. Effects of a combination of β-carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996;334:1150-1155.